Single Ascending Dose Study of MYK-461 in Healthy Volunteers
Launched by MYOKARDIA, INC. · Feb 2, 2015
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Normal body mass index (BMI)
- • Normal LVEF
- • Normal electrocardiogram (ECG)
- • Females must not be breastfeeding and must be permanently sterilized or are postmenopausal.
- Exclusion Criteria:
- • Any structural abnormalities on echocardiography
- • Positive results of HIV test and/or seropositive for HCV or HBV.
About Myokardia, Inc.
Myokardia, Inc. is a biopharmaceutical company dedicated to the development of innovative therapies for the treatment of serious cardiovascular diseases, with a focus on precision medicine. Leveraging cutting-edge science and technology, Myokardia aims to address the unmet needs of patients suffering from genetic heart conditions, such as hypertrophic cardiomyopathy. The company is committed to advancing clinical research and fostering collaborations to bring transformative treatments to market, enhancing patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Jonathan C Fox, MD, PhD
Study Director
MyoKardia, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials